Callan Capital LLC Buys 3,091 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Callan Capital LLC raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 281.0% in the fourth quarter, Holdings Channel reports. The firm owned 4,191 shares of the pharmaceutical company’s stock after acquiring an additional 3,091 shares during the quarter. Callan Capital LLC’s holdings in Vertex Pharmaceuticals were worth $1,705,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Arlington Trust Co LLC grew its stake in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares in the last quarter. Fortitude Family Office LLC acquired a new stake in shares of Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Baystate Wealth Management LLC lifted its position in shares of Vertex Pharmaceuticals by 49.0% in the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth approximately $25,000. Finally, NBC Securities Inc. acquired a new position in Vertex Pharmaceuticals in the 3rd quarter valued at $34,000. 90.96% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock worth $5,203,249 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.1 %

NASDAQ:VRTX opened at $397.48 on Friday. The company has a market cap of $102.73 billion, a P/E ratio of 28.62, a P/E/G ratio of 1.87 and a beta of 0.35. The stock’s fifty day moving average price is $411.60 and its two-hundred day moving average price is $398.67. Vertex Pharmaceuticals Incorporated has a 1 year low of $320.01 and a 1 year high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. The firm had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter in the prior year, the business posted $3.33 earnings per share. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on VRTX shares. Wells Fargo & Company boosted their price objective on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target on the stock. in a research report on Wednesday, January 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $440.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Maxim Group lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Royal Bank of Canada boosted their price objective on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.